There is good news for patients suffering from type-one diabetes as they may soon be able to do away with their daily insulin dose to manage their blood-sugar levels.
Researchers have found that a peptide called caerulein can convert existing cells in the pancreas into those cells destroyed in type-one diabetes-insulin-producing beta cells.
"We have found a promising technique for type-one diabetics to restore the body's ability to produce insulin," said Fred Levine, a professor at Sanford-Burnham Medical Research Institute in the US.
"By introducing caerulein to the pancreas, we were able to generate new beta cells - the cells that produce insulin," Levine added.
The study first examined how mice in which almost all beta cells were destroyed - similar to humans with type-one diabetes - responded to injections of caerulein.
In those mice, but not in normal mice, they found that caerulein caused existing alpha cells in the pancreas to differentiate into insulin-producing beta cells.
The research team then examined human pancreatic tissue from type-one diabetics, finding strong evidence that the same process induced by caerulein also occurred in the pancreases of those individuals.
Caerulein is a peptide originally discovered in the skin of Australian Blue Mountains tree frogs.
It stimulates gastric, biliary, and pancreatic secretions, and has been used in humans as a diagnostic tool in pancreatic diseases.
An estimated over 300 million people worldwide are living with type-one diabetes.
The study appeared in the journal Cell Death and Disease.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
